China approved world's first invasive brain-computer interface chip

MIT Technology Review told the story of Dong Hui (Dong Hui), a 39-year-old resident of Henan Province in China, who was able to hold a pen in his hand again and write thanks to an implanted brain-computer interface. Six years ago, Dong suffered a spinal cord injury in a car accident and has been paralyzed below the neck ever since. Last autumn, sitting in his own backyard, he decided to check whether he could take a pen in his hand again — and, slowly but confidently, he managed to write using the device.

What happened to the patient

According to MIT Technology Review's account, Dong Hui's attempt was not a spontaneous experiment — it was the result of participation in clinical trials of an invasive brain-computer interface (BCI) implanted in him after the injury. The device reads brain signals and converts them into commands that control external equipment or, in this case, help the patient restore basic motor function — the ability to hold a pen and move it across paper. It is this ability, lost after cervical spinal cord injury, that is symbolically and practically important for people with complete paralysis below the neck.

• Patient — Dong Hui, 39 years old, Henan Province, China.
• Cause of disability — spinal cord injury in a car accident six years ago.
• Diagnosis — paralysis below the neck (tetraplegia).
• Result — with the help of an implanted brain-computer interface, the patient was able to hold a pen and write.
• Source of the story — journalism material from MIT Technology Review.

Why invasive BCI is a particular challenge

Invasive brain-computer interfaces differ from non-invasive ones in that electrodes are implanted directly into the brain or on its surface, rather than reading signals through the scalp. This provides significantly more accurate and faster signal, but requires neurosurgery, a long rehabilitation period, and strict regulatory oversight — which is why such devices spend years in clinical trial stages before receiving approval for broader clinical use. The industry of invasive BCIs in the world is still represented by a few players, and competition between American and Chinese developments in this area has become notably acute in recent years against the backdrop of general competition for leadership in neurotechnology.

Against the backdrop of stories like Dong Hui's, people often recall the most famous project in this field in the West — Neuralink, which is also engaged in developing implantable brain-computer interfaces. The comparison of Western and Chinese developments in recent years has become part of a broader picture of technological competition, where neurotechnologies are viewed as another strategic direction alongside large language models and chip manufacturing. For patients, however, the specific national origin of the developer is secondary — what matters much more is the speed with which such devices pass from experimental laboratory to routine clinical practice.

What this means for patients with paralysis

Dong Hui's story is instructive in that it translates the abstract conversation about "chips in the brain" into a concrete human result — the ability to perform once again a normal but critically important movement. For people with tetraplegia, recovery of even basic motor functions of the upper extremities dramatically changes the level of independence in daily life: the ability to write, and in the future — to control a computer, a wheelchair, or household appliances directly through a mental command. It is precisely such clinical demonstrations, rather than abstract technical specifications, that usually become the argument for regulators and the medical community in favor of further expansion of clinical trial programs.

In China, the development of neurotechnologies in recent years is called one of the priority scientific directions alongside other areas of AI, and the number of specialized laboratories and clinical centers working with brain-computer interfaces continues to grow. The story of a single patient like Dong Hui usually becomes the first public evidence that such programs are moving out of the stage of laboratory experiments into the stage of actual clinical stories — and it is on the basis of such stories that regulators make decisions about expanding trial programs and approving the technology for broader use.